The earnings call highlighted strong growth in the Pharmaceuticals division and successful product launches, but it also addressed significant financial challenges, litigation risks, and market difficulties in Consumer Health.
Company Guidance
During the third quarter of 2025, Bayer reported a slight increase in currency and portfolio-adjusted sales both for the quarter and year-to-date. Core earnings per share (EPS) rose by 7% to EUR 4.29, while the free cash flow was negative EUR 800 million, aligning with projections. The Crop Science division saw a moderate sales decline over nine months, although corn sales increased by 9% due to expanded U.S. acreage and a strong start to the LATAM season. Pharmaceuticals reported notable growth for Nubeqa and Kerendia, with increases of 60% and nearly 80% year-over-year, respectively. However, Eylea sales declined due to pricing pressures in Japan and Canada. The Consumer Health segment faced challenges in the U.S. and China, prompting a lowered 2025 sales growth expectation, yet it remained committed to achieving an EBITDA margin between 23% and 24%. Overall, the company is poised to meet its upgraded 2025 guidance, despite challenges like Xarelto sales declines and currency headwinds, while looking forward to growth from new products like Beyonttra and Lynkuet, recently approved by the FDA.
Pharmaceuticals Division Growth
Nubeqa sales increased by 60% year-over-year and Kerendia sales increased by nearly 80%, driven by strong growth in the U.S. and China.
Record Uptake of Beyonttra
Beyonttra achieved around 50% market share in new to brand prescriptions in Germany, marking one of the fastest uptakes of a cardiovascular treatment.
Crop Science Corn Segment Growth
Corn sales rose by 22% due to acreage expansion in the U.S. and a strong start to the Latin American season.
FDA Approval of Lynkuet
Lynkuet received FDA approval and is expected to reach the U.S. market this month.
Bayer (BAYRY) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BAYRY Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2025
$7.95
$8.42
+5.95%
Aug 06, 2025
$8.02
$7.26
-9.45%
May 13, 2025
$6.68
$6.90
+3.29%
Mar 05, 2025
$6.17
$6.57
+6.47%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bayer AG (BAYRY) report earnings?
Bayer AG (BAYRY) is schdueled to report earning on Mar 03, 2026, Before Open (Confirmed).
What is Bayer AG (BAYRY) earnings time?
Bayer AG (BAYRY) earnings time is at Mar 03, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.